Announcement: New Editors at EBGI

Posted on August 19, 2026

Welcome New Editors Evidence-Based GI is pleased to welcome 12 new Associate Editors to the team. We look forward to reading…

ESD vs TAMIS for Early Rectal Neoplasms

Posted on

Rectal lesions with a risk of superficial submucosal invasion require en-bloc local resection to enable accurate histopathologic staging, assess resection margins, and determine whether additional radical surgery is necessary. In addition, in early superficial submucosal invasive rectal adenocarcinoma with favorable histologic features…an R0 resection can be considered curative. While ESD and TAMIS can both achieve en-bloc resection, prior comparative studies were largely retrospective, and DSETAMIS-2018 is a randomized controlled trial directly comparing the 2 approaches. The trial supports ESD as a potentially organ-preserving alternative to TAMIS in carefully selected early rectal neoplasms. Beyond comparable short-term local control, ESD avoided conversion to another approach, reduced hospitalization, and substantially lowered direct costs.

Low-Dose Aspirin Chemoprevention in Lynch Syndrome

Posted on

This evidence based summary reviews the results of the CaPP3 trial, which did not formally demonstrate non-inferiority of either 100 mg or 300 mg aspirin compared with 600 mg, but the overall findings are very encouraging.

Family-Based Obesity Treatment in Primary Care: An Upstream Strategy for Metabolic and Liver Health

Posted on

For gastroenterologists and hepatologists, childhood obesity is not only a pediatric primary-care issue; it is an early determinant of metabolic dysfunction-associated steatotic liver disease (MASLD), cardiometabolic risk, and future adult digestive disease burden. TEAM UP is therefore relevant to GI practice because it tests whether an evidence-based obesity intervention can be delivered earlier, closer to where families receive routine care, and before obesity-related liver and metabolic complications become entrenched.

Bepirovirsen Treatment for Chronic Hepatitis B Virus Infection

Posted on

The B-Well phase 3 trials represent a significant milestone toward an accessible cure of hepatitis B. By adding a single investigational agent (bepirovirsen) for a fixed 24-week duration, nearly a fifth of selected patients achieved a functional cure and completely freed themselves from baseline background therapy

Colonoscopy and FIT Shift CRC Detection Toward Earlier Stages: Results from the SCREESCO Trial

Posted on

For patients and providers trying to understand the benefits and risks of CRC screening via colonoscopy or FIT, the SCREESCO study provides valuable data we can share with our patients to help them make informed decisions. An important caveat in extrapolating the FIT data from this study to patients in the United States is to highlight that while the SCREESCO trial used a two-stool FIT protocol, we typically perform annual single-sample testing in the United States. 

AI-Assisted Endoscopy: Can AI Change Gastric Cancer Detection?

Posted on

This trial tempers enthusiasm for immediate widespread adoption of AI-assisted EGD as a tool to improve gastric neoplasm detection rates in high-volume, experienced endoscopy settings. However, the significant reduction in blind spots supports the use of AI as a quality monitoring tool during EGD.

Beyond Graft Survival: A Practical Guide to Long-Term Care After Liver Transplantation

Posted on

One of the most notable observations is the unexpectedly high burden of CKD among liver transplant recipients. The EVEROLIVER registry makes a compelling case for early reduction in calcineurin inhibitors and conversion to mTOR inhibitors, while conversion after 12 months provided no benefit. These data suggest a narrow therapeutic window during which renal recovery remains achievable.

Patients With Advanced Adenomas on Index Exam are at Increased Risk for Metachronous Advanced Neoplasia at Second Surveillance

Posted on

I follow the USMSTF for CRC recommendations for post polypectomy which currently suggest a 5-year follow up for these patients. These data support that recommendation by demonstrating that the risk for these patients is elevated at second surveillance colonoscopy and is independent of known risk factors as well as the adenoma detection rates of the endoscopists performing the colonoscopies.